TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Two late-breaking OPTIMAL trials are scheduled to present at the American Heart Association’s Nov. 7–9, 2026, scientific meeting, testing intensive blood pressure control in groups excluded from SPRINT: ischemic stroke survivors and higher-risk adults with type 2 diabetes. The trials target systolic pressure below 120 mmHg; their results and implications are not yet available in the supplied report.
The American Heart Association’s scientific meeting is scheduled to present results Saturday from two trials testing intensive blood pressure control in patient groups excluded from the landmark SPRINT study: ischemic stroke survivors and higher-risk adults with type 2 diabetes. Both OPTIMAL studies tested a systolic blood pressure target below 120 mmHg, and their findings could help address evidence gaps for patients not represented in SPRINT.
The trials, called OPTIMAL-Stroke and OPTIMAL-Diabetes, are among the first late-breaking presentations at the meeting, according to MedPage Today’s Nov. 6 report. The studies enrolled people whose starting systolic blood pressure was between 130 and 180 mmHg and examined a target of less than 120 mmHg for cardiovascular protection.
OPTIMAL-Stroke focused on people who had survived an ischemic stroke. OPTIMAL-Diabetes studied higher-risk participants with type 2 diabetes. The report identifies both groups as populations left out of SPRINT, a trial whose findings contributed to changes in how hypertension was defined nationally in 2017.
The report says the AHA’s main scientific sessions run Nov. 7–9, with expanded programming beginning Nov. 6. The meeting is being held in Chicago, with livestreaming available for selected sessions. It does not provide outcome data from either OPTIMAL trial, so the direction and size of any treatment effects remain unknown.
Evidence Beyond SPRINT’s Participants
The presentations matter because clinicians need evidence that applies to the people they treat, not just to participants in a landmark study. Since SPRINT excluded people with prior stroke and diabetes, its results alone cannot settle whether the same intensive target is beneficial or appropriate for those groups.
Testing a systolic target below 120 mmHg in these populations could inform future research and clinical discussions. But a target tested in a trial is not, by itself, a recommendation for every patient. The supplied report does not state the OPTIMAL studies’ results, report safety outcomes, or say whether the findings will change guidelines. Those details will be needed to understand the practical implications.
Products Worth Considering
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
Levoit Eleva 500X HEPA Air Purifier for Large Rooms
Levoit Core 400S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
The SPRINT Evidence Gap
SPRINT was a landmark blood pressure trial conducted more than a decade ago. MedPage Today reports that its findings contributed to the 2017 national redefinition of hypertension. The same report says people with prior stroke and people with diabetes were among the patient groups not included in SPRINT, leaving questions about applying its evidence to them.
The OPTIMAL trials are part of a broader AHA program testing established treatments and new approaches in cardiovascular care. Other scheduled topics include statin discontinuation, coronary procedures for stable ischemic heart disease, therapies targeting inflammation and lipoprotein(a), pacing strategies, a drug for sleep apnea, and AI-enabled smartwatch ECGs. The source describes the program; it does not provide new findings on those topics.
““two separate trials of intensive BP control that are expected to fill major gaps left by the landmark SPRINT trial””
— MedPage Today, reporting on the AHA meeting
Trial Outcomes Still Pending
The supplied report previews the presentations but gives no OPTIMAL outcome data. It is not yet clear whether either trial found that targeting systolic pressure below 120 mmHg reduced cardiovascular events, how the results compared with a less intensive target, or what adverse effects occurred.
The report also does not provide the studies’ participant counts, follow-up periods, detailed eligibility criteria, or authors’ conclusions. Without those details, readers cannot judge the size, reliability, or clinical reach of any reported effect. A trial result would also need to be considered alongside the full evidence base before it could support a change in care recommendations.
Saturday’s OPTIMAL Presentations
The next development is the scheduled presentation of OPTIMAL-Stroke and OPTIMAL-Diabetes on Saturday, Nov. 7, during the AHA meeting’s early late-breaking sessions. The meeting runs through Nov. 9, and selected sessions will be livestreamed. The source report does not specify presentation times or say when full results or peer-reviewed publications will be available.
When results are released, key details to watch include the blood pressure achieved in each study group, cardiovascular outcomes, safety findings, the length of follow-up, and how investigators interpret the results for people with stroke or diabetes. Until those details are available, the meeting preview establishes what the trials are testing, not whether intensive control should be adopted for these groups.
Key Questions
What are the OPTIMAL trials testing?
The two trials tested intensive blood pressure control, with a target systolic pressure below 120 mmHg, in people starting between 130 and 180 mmHg. OPTIMAL-Stroke studied ischemic stroke survivors; OPTIMAL-Diabetes studied higher-risk adults with type 2 diabetes.
Why are these studies relevant to SPRINT?
According to MedPage Today, people with prior stroke and people with diabetes were excluded from SPRINT. The OPTIMAL studies address evidence gaps for those populations, but their results are not included in the supplied report.
Have the trials shown that a target below 120 mmHg is better?
The source is a preview of the presentations and does not report the trials’ findings. Whether the target improved outcomes or affected safety remains unclear until results are reported.
When and where will the findings be presented?
The presentations are scheduled for Saturday, Nov. 7, 2026, at the American Heart Association scientific meeting in Chicago. The meeting’s main sessions run Nov. 7–9, with selected sessions streamed online.
Source: medpagetoday.com
